CN113244188A - Delivery system and fat degradation system based on yeast protein complex specialty - Google Patents
Delivery system and fat degradation system based on yeast protein complex specialty Download PDFInfo
- Publication number
- CN113244188A CN113244188A CN202110453048.8A CN202110453048A CN113244188A CN 113244188 A CN113244188 A CN 113244188A CN 202110453048 A CN202110453048 A CN 202110453048A CN 113244188 A CN113244188 A CN 113244188A
- Authority
- CN
- China
- Prior art keywords
- delivery system
- fat
- protein complex
- cells
- professional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of yeast protein, and particularly relates to a delivery system and a fat degradation system based on yeast protein complex speciality, which comprises a protein complex PORTANAR7 and a carrier delivery system, wherein the protein complex PORTANAR7 is a patent yeast expression product, and the carrier delivery system specializes. The invention enables the PORTANAR7 to target fat cells by arranging a professional carrier delivery system, thoroughly degrades intracellular triglyceride into carbon dioxide and water, and discharges the carbon dioxide and the water out of the body through breathing and sweat; after triglyceride is degraded, the compact components reduce the volume of fat cells by promoting cells to form endocytic vacuoles and drive surrounding matrixes to realize the compact state of the whole adipose tissues, the targeted fat reduction and compact effect can be realized without wound and without damaging fat cells and tissues through the professional fat degradation system and the carrier delivery system, fat globules are reduced by 2 times in 15 minutes, and the fat globules are compacted by 2-3cm immediately.
Description
Technical Field
The invention relates to the technical field of yeast protein, in particular to a delivery system and a fat degradation system based on yeast protein complex speciality.
Background
Yeast protein is a high quality complete protein present in natural yeast. The first time that yeast, Candida utilis (Candida utilis) and saccharomyces cerevisiae, were used as food products, their protein content was more than half of the dry weight, but the essential amino acid composition is relatively deficient in sulfur-containing amino acids, so their biovalue can be increased by the addition of methionine.
Yeast protein, also called microbial protein, is a single-cell protein, and is mainly the main ingredient of microbial thallus such as yeast, bacteria, fungi and microalgae artificially cultured by using byproducts or wastes of industrial, agricultural and petroleum industries as raw materials. The nucleotide yeast is a functional yeast prepared by continuously fermenting yeast by utilizing molasses and starch sugar, and separating, concentrating, breaking the wall, performing directional enzymolysis, drying and crushing fermentation liquor, wherein the protein content in the yeast is higher than 50 percent of that of soybean protein, and the yeast contains more amino acid active groups, so that a good adhesive molecular structure can be formed.
In a broad sense, gene therapy systems can be divided into viral vector-mediated systems and non-viral vector-mediated systems. Viral vectors are constructed using retrovirus or adenovirus and have the advantage of high transfection efficiency into cells. However, viral vectors have problems associated with immunogenicity in vivo and suffer from inherent problems associated with gene recombination. Adipocytes, particularly mature obese adipocytes, which are terminally differentiated cells and thus difficult to transfect, have been transfected using electroporation in previous studies, but the transfection efficiency reported was only about 10%. Furthermore, in an in vivo gene delivery system, this method has not attempted to selectively deliver a gene to a target adipose tissue.
Disclosure of Invention
Based on the technical problem that the method has not attempted to selectively deliver genes to target adipose tissues in an in vivo gene delivery system proposed in the background art, the present invention proposes a yeast protein complex-based professional delivery system and a fat degradation system.
The invention provides a professional delivery system based on a yeast protein complex, which comprises a protein complex PORTANAR7 and a carrier delivery system, wherein the protein complex PORTANAR7 is an expression product of a patent yeast, and the professional carrier delivery system enables the PORTANAR7 to target fat cells and completely degrade triglyceride in the cells into carbon dioxide and water which are discharged out of the body through breathing and sweat; after triglyceride is degraded, the compact components reduce the volume of fat cells by promoting cells to form endocytic vesicles, and draw surrounding matrixes to realize the compact state of the whole adipose tissue.
Preferably, the carrier delivery system takes a cationic material for encapsulating the drug as a core, a polymer material as an intermediate layer and a cell membrane as an outer layer.
Preferably, the gene is electrostatically bound to the cationic material and the nanocrystals of the protein complex, PORTANAR7, to form a nanocrystalline gene complex, the protein complex, PORTANAR7, having a diameter of 200nm or less.
Preferably, the cell membrane is a biogenic cell membrane, or a mixed membrane of two cells; the medicine is nucleic acid medicine.
A yeast protein compound based professional fat degradation system comprises targeted fat cells and a fat degradation system, and the effects of targeted fat reduction and compaction can be achieved noninvasively without damaging fat cells and tissues through the professional fat degradation system and a carrier delivery system.
Preferably, the targeted adipocytes are differentiated mature obese adipocytes, and the targeted adipocytes are mature obese adipocytes from 9 to 11 days after the start of differentiation.
Preferably, the therapeutic gene for treating obesity and obesity-induced metabolic syndrome in the fat degradation system is DNA or RNAi.
Preferably, the RNAi is an siRNA or shRNA.
The beneficial effects of the invention are as follows:
the delivery system and the fat degradation system based on the yeast protein compound speciality enable the PORTANAR7 to target fat cells by arranging the carrier delivery system specializedly, completely degrade triglyceride in the cells into carbon dioxide and water, and discharge the carbon dioxide and the water out of the body through breathing and sweat; after triglyceride is degraded, the compact components reduce the volume of fat cells by promoting cells to form endocytic vacuoles and drive surrounding matrixes to realize the compact state of the whole adipose tissues, the targeted fat reduction and compact effect can be realized without wound and without damaging fat cells and tissues through the professional fat degradation system and the carrier delivery system, fat globules are reduced by 2 times in 15 minutes, and the fat globules are compacted by 2-3cm immediately.
The parts of the device not involved are the same as or can be implemented using prior art.
Detailed Description
The technical solution of the present patent will be described in further detail with reference to the following embodiments.
Reference will now be made in detail to embodiments of the present patent, examples of which are illustrated in the accompanying documents, wherein like reference numerals refer to the same or similar elements or elements having the same or similar functions throughout. The embodiments described below by reference to the documents are exemplary only for the purpose of explaining the present patent and are not to be construed as limiting the present patent.
In the description of this patent, it is to be understood that the terms "center," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," and the like are used in the positional or orientational relationships indicated by the documents to facilitate the description of the patent and to simplify the description, but are not intended to indicate or imply that the referenced device or element must have a particular orientation, be constructed and operated in a particular orientation, and are not to be construed as limiting the patent.
In the description of this patent, it is noted that unless otherwise specifically stated or limited, the terms "mounted," "connected," and "disposed" are to be construed broadly and can include, for example, fixedly connected, disposed, detachably connected, disposed, or integrally connected and disposed. The specific meaning of the above terms in this patent may be understood by those of ordinary skill in the art as appropriate.
A delivery system based on yeast protein complex specialization comprises a protein complex PORTANAR7 and a carrier delivery system, wherein the protein complex PORTANAR7 is an expression product of patent yeast, and the carrier delivery system specializes in, so that the PORTANAR7 can target fat cells and completely degrade triglyceride in the cells into carbon dioxide and water which are discharged out of the body through breathing and sweat; after triglyceride is degraded, the compact components reduce the volume of fat cells by promoting cells to form endocytic vesicles, and draw surrounding matrixes to realize the compact state of the whole adipose tissue.
In the invention, the carrier delivery system takes a cationic material for encapsulating the drug as a core, a polymer material as a middle layer and a cell membrane as an outer layer.
In the present invention, the gene is electrostatically bound to the cationic material and the nanocrystal of the protein complex, PORTANAR7, to form a nanocrystal gene complex, and the protein complex, PORTANAR7, has a diameter of 200nm or less.
In the invention, the cell membrane is a biological source cell membrane, or a mixed membrane of two cells; the medicine is nucleic acid medicine.
A yeast protein compound-based professional fat degradation system comprises targeted fat cells and a fat degradation system, and achieves the effects of targeted fat reduction and compaction in a noninvasive mode without damaging fat cells and tissues through the professional fat degradation system and a carrier delivery system.
In the present invention, the targeted adipocytes are differentiated mature obese adipocytes, and the targeted adipocytes are mature obese adipocytes from 9 to 11 days after the start of differentiation.
In the present invention, the therapeutic gene for obesity and obesity-induced metabolic syndrome in the fat degradation system is DNA or RNAi.
In the present invention, RNAi is siRNA or shRNA.
The PORTANAR7 can target fat cells and completely degrade triglyceride in the cells into carbon dioxide and water, and the carbon dioxide and the water are discharged out of the body through breathing and sweat by arranging a professional carrier delivery system; after triglyceride is degraded, the compact components reduce the volume of fat cells by promoting cells to form endocytic vacuoles and drive surrounding matrixes to realize the compact state of the whole adipose tissues, the targeted fat reduction and compact effect can be realized without wound and without damaging fat cells and tissues through the professional fat degradation system and the carrier delivery system, fat globules are reduced by 2 times in 15 minutes, and the fat globules are compacted by 2-3cm immediately.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
In the description of this patent, it is to be understood that the terms "center," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," and the like are used in the positional or orientational relationships indicated by the documents to facilitate the description of the patent and to simplify the description, but are not intended to indicate or imply that the referenced device or element must have a particular orientation, be constructed and operated in a particular orientation, and are not to be construed as limiting the patent.
In the description of this patent, it is noted that unless otherwise specifically stated or limited, the terms "mounted," "connected," and "disposed" are to be construed broadly and can include, for example, fixedly connected, disposed, detachably connected, disposed, or integrally connected and disposed. The specific meaning of the above terms in this patent may be understood by those of ordinary skill in the art as appropriate.
Claims (8)
1. A delivery system based on yeast protein complex specialization, comprising a protein complex PORTANAR7 and a carrier delivery system, wherein the protein complex PORTANAR7 is a patent yeast expression product, and the carrier delivery system specializes in enabling the PORTANAR7 to target fat cells and completely degrade triglyceride in the cells into carbon dioxide and water which are discharged out of the body through respiration and sweat; after triglyceride is degraded, the compact components reduce the volume of fat cells by promoting cells to form endocytic vesicles, and draw surrounding matrixes to realize the compact state of the whole adipose tissue.
2. The yeast protein complex specialty-based delivery system of claim 1, wherein said carrier delivery system has drug-encapsulated cationic material as core, polymer material as middle layer, and cell membrane as outer layer.
3. A yeast protein complex specialty-based delivery system according to claim 2, wherein said genes are electrostatically bound to the cationic material and nanocrystals of protein complex poranar 7 to form a nanocrystalline gene complex, said protein complex poranar 7 having a diameter of 200nm or less.
4. A yeast protein complex professional based delivery system according to claim 3, wherein the cell membrane is a biogenic cell membrane or a mixed membrane of two cells; the medicine is nucleic acid medicine.
5. A yeast protein compound based professional fat degradation system comprises targeted fat cells and a fat degradation system, and is characterized in that the targeted fat reduction and compaction effects can be achieved noninvasively without destroying fat cells and tissues through the professional fat degradation system and a carrier delivery system.
6. A yeast protein complex-based professional lipolysis system according to claim 5, wherein said targeted adipocytes are differentiated mature obese adipocytes, and the targeted adipocytes are mature obese adipocytes from day 9 to day 11 after the start of differentiation.
7. A yeast protein complex-based professional lipolysis system according to claim 6 wherein the therapeutic gene for the treatment of obesity and obesity-induced metabolic syndrome in said lipolysis system is DNA or RNAi.
8. The yeast protein complex-based professional lipolysis system of claim 7, wherein the RNAi is siRNA or shRNA.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110453048.8A CN113244188A (en) | 2021-04-26 | 2021-04-26 | Delivery system and fat degradation system based on yeast protein complex specialty |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110453048.8A CN113244188A (en) | 2021-04-26 | 2021-04-26 | Delivery system and fat degradation system based on yeast protein complex specialty |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113244188A true CN113244188A (en) | 2021-08-13 |
Family
ID=77221650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110453048.8A Pending CN113244188A (en) | 2021-04-26 | 2021-04-26 | Delivery system and fat degradation system based on yeast protein complex specialty |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113244188A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111803653A (en) * | 2020-06-27 | 2020-10-23 | 苏州大学 | Gene delivery system capable of removing mixed cell membrane coating and preparation method and application thereof |
-
2021
- 2021-04-26 CN CN202110453048.8A patent/CN113244188A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111803653A (en) * | 2020-06-27 | 2020-10-23 | 苏州大学 | Gene delivery system capable of removing mixed cell membrane coating and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 星医联: "瑾姝•雕刻家", 《公众号：星医联》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101633916B (en) | Superoxide dismutase and preparation method thereof | |
| WO2021077856A1 (en) | Sirna and nano delivery system capable of silencing pcsk9 protein, and application of nano delivery system | |
| CN109762821B (en) | Interfering RNA for inhibiting expression of AFAP1-AS1 and application of interfering RNA in increasing sensitivity of breast cancer radiotherapy | |
| CN108553650A (en) | A kind of bionic nano red blood cell genophore and the preparation method and application thereof | |
| Liu et al. | Small extracellular vesicles: Yields, functionalization and applications in diabetic wound management | |
| CN113244188A (en) | Delivery system and fat degradation system based on yeast protein complex specialty | |
| CN104263744B (en) | A kind of engineered glucose oxidase gene and its Expression and Application | |
| CN108721633A (en) | A kind of polypeptide nano bubble and its preparation method and application | |
| EP2860255A1 (en) | Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells | |
| CN114958850B (en) | Gene component, delivery system containing gene component and application of gene component | |
| CN116622774A (en) | Vector for macrophage targeting expression of ACOD1 gene, nucleic acid medicine and application of nucleic acid medicine in preventing and treating renal ischemia reperfusion | |
| CN114788876B (en) | MRNA (messenger ribonucleic acid) medicinal preparation for treating diabetes and preparation method and application thereof | |
| CN113521309B (en) | Application of human hepatocyte growth factor gene in treatment of eczema and microneedle medicine instrument | |
| AU2016235674B2 (en) | Transformant used for losing weight and reducing fat, construction method for transformant, and application of transformant | |
| CN101418257A (en) | A kind of donkey hide gelatin grape health wine and production technique thereof | |
| CN108619529A (en) | A kind of nanometer formulation and its preparation method and application recombinantly expressing gene containing IL12 | |
| Kontogiannis et al. | On the in vivo kinetics of gene delivery vectors | |
| CN104356199B (en) | A kind of degradable genophore of polypeptide of stearoyl modification and preparation method and application | |
| CN101444629B (en) | Non-injection gene therapy medicine and medicine box thereof | |
| Zhang et al. | Gene expression and antitumor effect following im electroporation delivery of human interferon alpha2 gene | |
| CN104497168A (en) | Aminoalkyl derivative of chitosan | |
| CN104922698B (en) | Human stem cell growth parenteral solution and preparation method thereof | |
| US20240026311A1 (en) | ARTIFICIALLY SYNTHESIZED mRNA AND USE OF SAME | |
| CN112107696A (en) | Innovative gene therapy medicine for special route administration and medicine box thereof | |
| CN107058223A (en) | A kind of nutrient solution for immunocyte culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220516 Address after: Building C, No.888, Huanhu West 2nd Road, Lingang New District, Pudong New Area pilot Free Trade Zone, Shanghai Applicant after: Shanghai xingyilian Technology Co.,Ltd. Address before: Room 1504, floor 15, No. 2, keying Road, Suzhou Industrial Park, Suzhou, Jiangsu 215000 Applicant before: Suzhou xingyilian Supply Chain Management Co.,Ltd. |
|
| TA01 | Transfer of patent application right |